Table 2.
Newcastle-Ottawa score and funding source for included cohort studies
| Study | Representativeness of the exposed cohort | Selection of the non-exposed cohort | Ascertainment of exposure | Demonstration that outcome of interest was not present at start of study | Comparability of cohorts on the basis of the design or analysis | Assessment of outcome | Was follow-up long enough for outcomes to occur? | Total score | Funding source |
| Borut Jug25 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 7 | No description |
| Carmo44 | 1 | 1 | 1 | 1 | 0 | NA | NA | 4 | No description |
| Fitzsimons26 27 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | * | No description |
| Martens20 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 7 | Vifor Pharma |
NA, not available.